Free Trial

MacroGenics (MGNX) Competitors

MacroGenics logo
$1.58 +0.09 (+6.04%)
Closing price 04:00 PM Eastern
Extended Trading
$1.58 -0.01 (-0.32%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MGNX vs. PRTA, AUTL, KMDA, VERV, ORKA, RVNC, SANA, FULC, ABVX, and RAPP

Should you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Prothena (PRTA), Autolus Therapeutics (AUTL), Kamada (KMDA), Verve Therapeutics (VERV), Oruka Therapeutics (ORKA), Revance Therapeutics (RVNC), Sana Biotechnology (SANA), Fulcrum Therapeutics (FULC), ABIVAX Société Anonyme (ABVX), and Rapport Therapeutics (RAPP). These companies are all part of the "pharmaceutical products" industry.

MacroGenics vs.

MacroGenics (NASDAQ:MGNX) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 13.0% of MacroGenics shares are owned by insiders. Comparatively, 9.2% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, MacroGenics had 4 more articles in the media than Prothena. MarketBeat recorded 11 mentions for MacroGenics and 7 mentions for Prothena. Prothena's average media sentiment score of 1.30 beat MacroGenics' score of 0.17 indicating that Prothena is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MacroGenics
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Prothena
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Prothena received 189 more outperform votes than MacroGenics when rated by MarketBeat users. Likewise, 70.56% of users gave Prothena an outperform vote while only 61.88% of users gave MacroGenics an outperform vote.

CompanyUnderperformOutperform
MacroGenicsOutperform Votes
427
61.88%
Underperform Votes
263
38.12%
ProthenaOutperform Votes
616
70.56%
Underperform Votes
257
29.44%

MacroGenics has a net margin of -69.07% compared to Prothena's net margin of -90.50%. Prothena's return on equity of -22.67% beat MacroGenics' return on equity.

Company Net Margins Return on Equity Return on Assets
MacroGenics-69.07% -89.42% -38.57%
Prothena -90.50%-22.67%-19.68%

MacroGenics has a beta of 2.2, suggesting that its share price is 120% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500.

MacroGenics has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MacroGenics$152.43M0.65-$9.06M-$0.89-1.78
Prothena$137.94M2.56-$147.03M-$2.08-3.15

MacroGenics presently has a consensus price target of $6.13, suggesting a potential upside of 287.66%. Prothena has a consensus price target of $51.71, suggesting a potential upside of 689.53%. Given Prothena's stronger consensus rating and higher possible upside, analysts clearly believe Prothena is more favorable than MacroGenics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MacroGenics
0 Sell rating(s)
7 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.40
Prothena
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.88

Summary

Prothena beats MacroGenics on 10 of the 18 factors compared between the two stocks.

Get MacroGenics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MGNX vs. The Competition

MetricMacroGenicsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$99.68M$6.48B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-1.009.0626.7119.71
Price / Sales0.65251.50386.13120.55
Price / CashN/A65.8538.2534.62
Price / Book0.646.456.774.50
Net Income-$9.06M$143.98M$3.23B$248.22M
7 Day Performance2.60%2.41%1.80%0.56%
1 Month Performance3.95%4.56%11.10%13.17%
1 Year Performance-66.38%-2.67%17.11%7.30%

MacroGenics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MGNX
MacroGenics
3.6839 of 5 stars
$1.58
+6.0%
$6.13
+287.7%
-65.0%$99.68M$152.43M-1.00430News Coverage
Analyst Forecast
Analyst Revision
PRTA
Prothena
3.855 of 5 stars
$7.40
+3.1%
$51.71
+598.8%
-68.5%$398.32M$137.94M-3.22130Positive News
AUTL
Autolus Therapeutics
3.096 of 5 stars
$1.48
+11.3%
$9.32
+529.7%
-62.0%$393.89M$9.01M-1.22330High Trading Volume
KMDA
Kamada
3.9227 of 5 stars
$6.82
-1.7%
$14.67
+115.1%
+28.9%$392.01M$160.95M24.36360Analyst Upgrade
Analyst Revision
VERV
Verve Therapeutics
3.513 of 5 stars
$4.37
-5.6%
$25.75
+489.2%
-23.6%$389.56M$59.61M-1.78110Trending News
Analyst Upgrade
Analyst Revision
ORKA
Oruka Therapeutics
2.3453 of 5 stars
$10.31
+2.5%
$39.86
+286.6%
N/A$386.02MN/A-1.65N/ANews Coverage
Analyst Forecast
Analyst Revision
Gap Up
RVNC
Revance Therapeutics
2.5932 of 5 stars
$3.65
flat
$8.45
+131.5%
N/A$381.02M$234.04M-1.89500News Coverage
Analyst Forecast
SANA
Sana Biotechnology
2.43 of 5 stars
$1.68
-3.7%
$10.80
+542.9%
-76.4%$378.80MN/A-1.20380Gap Down
FULC
Fulcrum Therapeutics
0.7835 of 5 stars
$6.93
+0.7%
$4.50
-35.1%
-18.2%$374.07M$80M-22.35100
ABVX
ABIVAX Société Anonyme
2.4466 of 5 stars
$5.88
-2.2%
$34.00
+478.2%
-59.3%$372.90MN/A0.0061
RAPP
Rapport Therapeutics
1.5228 of 5 stars
$10.19
+2.3%
$32.67
+220.6%
N/A$371.92MN/A-2.95N/A

Related Companies and Tools


This page (NASDAQ:MGNX) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners